ALCOBRA PHARMACEUTICALS
Alcobra Pharmaceuticals Inc., which is developing a treatment for attention deficit hyperactivity disorder (ADHD) held its Nasdaq IPO last night (Israel time). Sources said that the company had obtained positive feedback during its road show. Just before the road show, the company expanded its prospectus from issuing 1.36 million share to 2.27 million shares. Alcobra held the offering at $8 per share, raising a gross $25 million at a company value of $89 million. The company had hoped to raise the money at a share proce of between $10 and $12. It will be traded under the ticker "ADHD".
ALCOBRA PHARMACEUTICALS
Social Links:
Industry:
Biotechnology
Founded:
2008-01-01
Address:
Tel Aviv, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.alcobra-pharma.com
Total Employee:
11+
Status:
Active
Contact:
+972 72-220-4661
Email Addresses:
[email protected]
Total Funding:
28.5 M ILS
Technology used in webpage:
Japanese Server Location
Similar Organizations
Akcea Therapeutics
Akcea Therapeutics is a development and commercialization company focused on helping patients living with serious and rare diseases.
Galenea
Galenea is engaged in developing therapeutics for central nervous system diseases.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Current Advisors List
Founder
Stock Details
Investors List
Cybele Holdings
Cybele Holdings investment in Post-IPO Equity - Alcobra Pharmaceuticals
Official Site Inspections
http://www.alcobra-pharma.com
- Host name: tk2-245-32345.vs.sakura.ne.jp
- IP address: 160.16.207.99
- Location: Osaka Japan
- Latitude: 34.6848
- Longitude: 135.5142
- Timezone: Asia/Tokyo
- Postal: 543-0062
More informations about "Alcobra Pharmaceuticals"
Alcobra Pharmaceuticals - Crunchbase Company …
Contact Email [email protected]; Phone Number +972 72-220-4661; Alcobra Pharmaceuticals Inc., which is developing a treatment for attention …See details»
Alcobra Pharmaceuticals
Feb 25, 2025 Alcobra Pharmaceuticals was founded in 2008 in Tel Aviv, Israel. The company has grown since then, establishing offices in the US and building a strong IP portfolio. Alcobra …See details»
Alcobra - LinkedIn
Alcobra Ltd., founded in 2008 and headquartered in Tel Aviv, Israel, is an emerging pharmaceutical company focused on the development of new medications to help patients …See details»
Alcobra Ltd. - VentureRadar
Alcobra Ltd. is a public, specialty pharmaceutical company. The company is focused on the development of new medications to help patients with cognitive disorders, including attention …See details»
Alcobra Company Profile - Office Locations, Competitors ... - Craft
Jun 1, 2018 Alcobra is a pharmaceutical company focused on the development of new medications to help patients with cognitive disorders including Attention Deficit Hyperactivity …See details»
Alcobra: ADHD IPO, Health Care - Israeli drug company …
May 21, 2013 Alcobra Priced, Nasdaq: ADHD. Israeli drug company developing a non-stimulant ADHD treatment. Industry: Health Care. First Day Return: -5.6%. Industry: Health Care. ...See details»
Alcobra Announces Cooperation Agreement with Brosh Group
Jun 12, 2017 The Cooperation Agreement also provides that Alcobra will continue its ongoing review of strategic alternatives and existing proposals by inviting additional proposals from …See details»
Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge
Sep 29, 2017 Home / More News / Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge. More News. Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge. Published on: …See details»
David Baker | Alcobra Pharma | Israel - OMICS International
Alcobra Pharma Israel. Biography. Mr. Baker joined Alcobra in January 2014 as the Chief Commercial Officer and effective June 1, 2017 was appointed interim CEO. Prior to joining …See details»
Alcobra Announces Leadership Update - GlobeNewswire
May 15, 2017 Alcobra continues its established process to explore options for creating shareholder value. The company is currently exploring strategic alternatives, which may …See details»
Alcobra abandons troubled lead drug after phase 3 failure
Jan 17, 2017 Alcobra took a body blow last year when the FDA placed a clinical hold on its lead drug metadoxine, but a failed phase 3 trial has now delivered a coup de grâce for the program.See details»
Alcobra Pharma Ltd. (ADHD) Stock Price Today, Quote ... - Stocktwits
Track Alcobra Pharma Ltd. (ADHD) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the …See details»
Alcobra Announces FDA Clearance of Protocol for Phase IIb
TEL AVIV, Israel, May 8, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development...See details»
Alcobra - LinkedIn
Alcobra | LinkedIn 팔로워 943명 | Alcobra Ltd., founded in 2008 and headquartered in Tel Aviv, Israel, is an emerging pharmaceutical company focused on the development of new …See details»
The Importance of Mentoring | PharmaVoice
Aug 1, 2015 David Baker Chief Commercial Officer, Alcobra Pharma I started a mentorship program that paired professionals at Shire with first-generation college students. The program …See details»
metadoxine - New Drug Approvals
Alcobra Ltd. A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition: WO2011061743A1 * Nov 18, 2010: May …See details»
RNA biotech Arcturus backs onto Nasdaq in Alcobra deal
Sep 28, 2017 The combined Arcturus-Alcobra biotech will have about $40 million in cash. Alcobra is expected to have $35 million at the time of closing, showing Arcturus is bringing a …See details»
Alcobra – Farmacia La Estrella – ALCOBRA®
ALCOBRA® nació hace más de 100 años en el sur del mundo. Conoce su historia. Ventajas El unico 100% original. El único 100% original. La marca está registrada desde el año 2013. No …See details»
Alcobra Announces IND Clinical Hold Affecting the MDX Phase
Sep 29, 2016 U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 [email protected] Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 …See details»
Alcobra Announces Results From Phase 2 Clinical Trial of
Jun 24, 2015 U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 [email protected] Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 …See details»